LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Strona główna・Stock List・Cogent Biosciences Inc

Cogent Biosciences Inc

Closed

38.79 -1.32

Buy Sell

Overview

Share price change

24h

Current

Min

38.16

Max

39.33

Key metrics
By Trading Economics
Income	-7.4M -81M
EPS	-0.5
Profit margin	-1,582.642
Employees	205
EBITDA	-6.8M -79M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+8.11% upside

Market Stats
By TradingEconomics
Market Cap	3.9B 6.1B
Previous open	40.11
Previous close	38.79

Technical Score

By Trading Central

Confidence

Bearish Evidence

4.88 / 5.87 Support & Resistance

Cogent Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 gru 2025, 21:08 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Buys AI-Device Maker Limitless

5 gru 2025, 19:39 UTC

Major Market Movers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 gru 2025, 19:17 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5 gru 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 gru 2025, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

5 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 gru 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 gru 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 gru 2025, 21:03 UTC

Market Talk

Earnings

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 gru 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 gru 2025, 20:42 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 gru 2025, 20:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 gru 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 gru 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 gru 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5 gru 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 gru 2025, 18:28 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:24 UTC

Acquisitions, Mergers, Takeovers

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 gru 2025, 18:20 UTC

Market Talk

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 gru 2025, 18:11 UTC

Market Talk

The Tale of Two Canadian Employment Indicators -- Market Talk

5 gru 2025, 17:48 UTC

Market Talk

Canadian Youth Unemployment Rate Cools -- Market Talk

5 gru 2025, 17:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

5 gru 2025, 17:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Correction to Imax Market Talk

5 gru 2025, 17:35 UTC

Market Talk

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5 gru 2025, 17:25 UTC

Market Talk

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Peer Comparison

Price change

Cogent Biosciences Inc Forecast

Price Target

By TipRanks

8.11% upside

12 Months Forecast

Average 42.5 USD 8.11%

High 65 USD

Low 20 USD

Based on 11 Wall Street analysts offering 12 month price targets forCogent Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Cogent Biosciences Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.88 / 5.87Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.